Brief: Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC
19/02/2026 22:46
Feb 19 (Reuters) - Bicara Therapeutics Inc BCAX.O: FICERAFUSP ALFA 2000MG Q2W DEMONSTRATES DEEP, DURABLE RESPONSES IN 1L R/M HPV-NEGATIVE HNSCC AND SUPPORTS DEVELOPMENT OF LESS FREQUENT DOSING REGIMEN BICARA THERAPEUTICS INC: PLANS TO DEVELOP A LOADING AND EVERY-THREE-WEEK MAINTENANCE REGIMEN FOR FICERAFUSP ALFA, PENDING REGULATORY ALIGNMENT Source text: ID:nGNX7kDHsZ Further company coverage: BCAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bicara Therapeutics
See all newsBrief: Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Bicara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Bicara Therapeutics Appoints Ryan Cohlhepp As President & CEO Effective January 2027
Brief: Bicara Therapeutics Announces Appointments Of Jeremy Bender And Christy Oliger To Board Of Directors